Announcement on the Acceptance of the Listing Application for Sacubitril Valsartan Amlodipine Tablets

Shenzhen Salubris Pharmaceuticals Co., Ltd.·July 22, 2026·2 pages

✨ AI Summary

Shenzhen Sanofi-Aventis announced that its self-developed product, Sacubitril Valsartan Amlodipine Tablets, has been accepted for listing by the National Medical Products Administration. This fixed-dose combination is the first of its kind globally and aims to offer a new treatment option for hypertension. The company expects it to strengthen its market position in hypertension treatment.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002294

Securities Abbreviation: Sanofi-Aventis

Number: 2026-061

Shenzhen Sanofi-Aventis Pharmaceutical Co., Ltd.

Announcement on the Acceptance of the Listing Application for Sacubitril Valsartan Amlodipine Tablets

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or material omissions.

Recently, Shenzhen Sanofi-Aventis Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") announced that its independently developed product "Sacubitril Valsartan Amlodipine Tablets" (Project Code: SAL0130) has been accepted by the National Medical Products Administration for its listing application. The relevant information is hereby announced as follows:

Basic Information of the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.